Bio-Thera(SH:688177) Xin Lang Cai Jing·2025-12-23 01:58Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a mixed performance in recent months, with a year-to-date increase of 21.93% but a decline of 21.13% over the past 60 days [2] - As of December 23, Baiotai's stock price was 23.63 yuan per share, with a market capitalization of 9.785 billion yuan and a trading volume of 816.40 million yuan [1] - The company has seen a net inflow of 794,500 yuan from major funds, with significant buying activity accounting for 15.09% of total trading [1] Group 2 - Baiotai's main business revenue composition includes 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to the parent company was -224 million yuan, reflecting a 38.72% increase [2] - As of September 30, 2025, the number of shareholders in Baiotai was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2]